Page 19 to 43: Estelle Delfosse and Caroline Mothe – Removing the obstacles to the adoption of innovative heating networks through translation | Page 45 to 66: Blandine Hetet, Laurence Lemoine and Samy Guesmi – The influence of the crowd on the collaborative innovation process: from expertise to contribution | Page 67 to 88: Ltifi Moez and Lubica Hikkerova – The determinants of intention to buy luxury brands online among young people | Page 89 to 106: Gonxhe Beqiri, Nora Sadiku-Dushi and Theranda Beqiri – The Application of Non-Fungible Token (NFT) in Marketing | Page 107 to 127: Raphael Lissillour, Jessica Gerard and Juraj Cheben – The determinants of frugality in times of crisis: a quantitative study of French consumers during the Covid-19 pandemic | Pages 129 to 156: Abdenasser Maaref, Abdelkader Djeflat, Khaled Guesmi and Jean-Michel Sahut – Key factors affecting harvesting knowledge from joint-venture to the local parent firm in the context of an emerging country | Page 157 to 175: Hubert de La Bruslerie – Point of view: Multiple share classes and shares with double voting rights: State of play and reasons for success.
Daily Archives
February 12, 2023
Common drugs that increase the risk of Alzheimer’s disease
written by Alexandra Hartman Editor-in-Chief
A new study suggests that anticholinergic drugs may increase the risk of accelerated cognitive decline. Especially in older people who are at high risk of developing Alzheimer’s disease.
Depression, urinary incontinence, seasonal allergies: the most prescribed drugs are the most at risk
Anticholinergic drugs block the action of acetylcholine, a chemical messenger that controls a range of automatic bodily functions and plays a vital role in memory and attention. Doctors prescribe these drugs for various conditions. Including urinary incontinence, overactive bladder, chronic obstructive pulmonary disease (COPD), seasonal allergies and depression.
However, over the past decade there has been growing evidence that anticholinergics may increase the risk of dementia in older adults. Researchers at the University of California, San Diego have now linked anticholinergics to mild cognitive impairment, which can lead to dementia, including Alzheimer’s disease.
The increased risk was particularly pronounced in people who had biomarkers of Alzheimer’s disease in their cerebrospinal fluid and in those who had an increased genetic risk of developing the disease. This interaction between anticholinergic drugs and biomarkers of Alzheimer’s risk is doubly effective. In the first case, biomarkers for Alzheimer’s disease indicate that the degeneration begins in a small region of the brain called the basal forebrain, which produces acetylcholine. Then, in the second case, anticholinergic drugs further deplete the brain’s acetylcholine stores. This combined effect has a very significant impact on a person’s thinking and memory.
A 47% increase in the risk of cognitive impairment
The study involved 688 people who participated in the Alzheimer’s Disease Neuroimaging Initiative. The participants had an average age of 74, and none showed signs of cognitive or memory problems at the start of the study. A third of them were taking at least one type of medication, with an average of 4.7 anticholinergic drugs per person. There were no differences in genetic risk factors between people taking anticholinergics and those not taking them.
However, depressive symptoms, total number of medications and heart problems were greater in people taking anticholinergics. So these variables were taken into account in all subsequent analyses. From the start of the study, participants took annual cognitive tests for up to 10 years.
Among those taking at least one anticholinergic, there was an overall 47% increased risk of mild cognitive impairment compared to those taking none. Those taking these drugs and who were genetically at risk of developing Alzheimer’s disease were more than 2.5 times more likely to develop mild cognitive impairment than those who were not taking the drugs and were not genetically at risk . Participants who had Alzheimer’s biomarkers in their cerebrospinal fluid at the start of the study and who were taking anticholinergics were almost 5 times more likely to show signs of mild cognitive impairment.
Source:
The results of the study are published in the journal Neurology.
https://n.neurology.org/content/early/2020/09/02/WNL.0000000000010643
* Presse Santé strives to transmit health knowledge in a language accessible to all. In NO CASE, the information given can not replace the opinion of a health professional.
Tags
antidepressants Alzheimer’s disease medications drugs related to Alzheimer’s disease
UAE Foreign Minister visits earthquake-hit area in Türkiye
written by Alexandra Hartman Editor-in-Chief
AA / Ankara / Merve Aydogan
Emirati media reported on Sunday that the UAE foreign minister visited the earthquake-affected areas in Kahramanmaras province, Türkiye.
The Emirati daily Al-Ittihad covered Sheikh Abdullah bin Zayed Al Nahyan’s visit to the region, making him the third foreign minister to visit the area since last Monday’s earthquakes.
Pledging to provide necessary support and assistance to Türkiye in the followingmath of the earthquakes, Al Nahyan also expressed his “sincere” condolences and sympathy for the victims of the earthquakes.
According to the daily, Al Nahyan also met with Turkish Interior Minister Suleyman Soylu.
The earthquakes caused extensive damage and more than 29,000 people lost their lives in southern and southeastern Türkiye, according to the latest reports.
A 7.7 magnitude earthquake struck Kahramanmaras province early on Monday. Nine hours later, an earthquake of magnitude 7.6, whose epicenter was also located in Kahramanmaras, shook the region, affecting several other provinces, including Adana, Adiyaman, Diyarbakir, Gaziantep, Hatay, Kilis, Malatya, Osmaniye and Sanliurfa.
The earthquake was also felt in neighboring countries in the region, including Lebanon and Syria.
*Translated from English by Mourad Belhaj
Only part of the dispatches, which Anadolu Agency broadcasts to its subscribers via the Internal Broadcasting System (HAS), is broadcast on the AA website, in a summarized manner. Please contact us to subscribe.
Benefits of adapting your energy contract: how ‘Easy’ households paid up to 1,500 euros more in four months than ‘Direct’
written by Alexandra Hartman Editor-in-Chief
The prices for February are already known for gas in Flow (monthly) and Easy (quarterly) type contracts: the Easy tariff is set at 14.993 cents per kWh, and the Flow tariff at 8.827. For average consumption, the difference will once more be approximately 160 euros just for the gas!
The prices of the “Direct” contract will not be known until the end of the month, since they depend on the wholesale prices of the month, but we are moving towards a further slight drop, and a gain which should be around 200 euros on a months unless prices panic.
With regard to electricity, prices seem to be stabilizing and we are moving towards prices that are barely higher than in January for Direct and Flow, but still at half the price of Easy.